ClinicalTrials.gg

Program

TPX-115

A development code. Also written as “TPX-115(allogeneic fibroblasts)”.

Its studies are mostly in Rotator Cuff Injuries, led by Tego Science.

Furthest: phase 3, since May 10, 20244 company-led studies, 3 open or runningNext primary completion: May 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tego Science43 open or runningphase 3since May 10, 2024Jul 3, 2020May 2027phase 2 · NCT07219654

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 3, 2020First study: phase 2 study in Rotator Cuff InjuriesFirst studyNCT04470167 · 49 enrolled · Korea, Republic of
  2. May 10, 2024Phase 3 study in Partial Thickness Rotator Cuff TearNCT06414005 · 166 planned · Korea, Republic of
  3. Jul 29, 2024Phase 1 study in Nasolabial Fold, HypoplasticNCT06533540 · 18 enrolled · South Korea
  4. Oct 20, 2025Phase 2 study in Partial Thickness Rotator Cuff TearsNCT07219654 · 60 planned · United States

Ahead

  1. May 2027Primary completion: phase 2 study in Partial Thickness Rotator Cuff TearsNCT07219654

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07219654Partial Thickness Rotator Cuff Tears · United States2RecruitingMay 202760
NCT06533540Nasolabial Fold, Hypoplastic · South Korea1Active, not recruitingMar 202618
NCT06414005Partial Thickness Rotator Cuff Tear · Korea, Republic of3RecruitingJun 30, 2026166
NCT04470167Rotator Cuff Injuries · Korea, Republic of2CompletedFeb 17, 202249

How it is read

Names in the registry

  • “TPX-115”, 3 entries
  • “TPX-115(allogeneic fibroblasts)”, 1 entry

Codes read as this program: TPX115.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.